Identifiants chercheur

Réseaux sociaux

    Export Publications

    Exporter les publications affichées :

    Widget extérieur

    Nombre de documents

    33

    Dr. Stéphane GIBAUD - MCU,PH


    Equipe CITHEFOR/EA3452 - Université de Lorraine

    Centre Hospitalier de l'Ouest Vosgien (Pharmacie à Usage Intérieur) : Pharmacien Gérant


    Article dans une revue32 documents

    • Jérémy Chambord, David Attivi, Thuus Véronique, Claire Zeghmouli, Stéphane Gibaud. The effect of intravenous isosorbide dinitrate in acute decompensated heart failure in hospital. International Journal of Clinical Pharmacy, 2017, 〈http://www.springer.com/-/1/AVtANxcGX4Rvx3H7v0qj〉. 〈10.1007/s11096-017-0459-x〉. 〈hal-01503313〉
    • Shefaat Ullah Shah, Marie Socha, Isabelle Fries, Stéphane Gibaud. Synthesis of S-nitrosoglutathione-alginate for prolonged delivery of nitric oxide in intestines. Drug Delivery, Taylor & Francis, 2016, 〈10.3109/10717544.2015.1122676〉. 〈hal-01288115〉
    • Kifayat Ullah Shah, Shefaat Ullah Shah, Naz Dilawar, Gul Majid Khan, Stéphane Gibaud. Thiomers and their potential applications in drug delivery. Expert Opinion on Drug Delivery, Taylor & Francis, 2016, 〈10.1080/17425247.2016.1227787〉. 〈hal-01377809〉
    • Feten Najlaoui, Pascal Pigeon, Zaineb Abdelkafi, Sebastien Leclerc, Pierrick Durand, et al.. Phthalimido-ferrocidiphenol cyclodextrin complexes: Characterization and anticancer activity. International Journal of Pharmaceutics, Elsevier, 2015, 491 (1-2), pp.323-334. 〈10.1016/j.ijpharm.2015.06.043〉. 〈hal-01218567〉
    • Shefaat Ullah Shah, Nuno Martinho, Marie Socha, Catarina Pinto Reis, Stéphane Gibaud. Synthesis and characterization of S-nitrosoglutathione-oligosaccharide-chitosan as a nitric oxide donor. Expert Opinion on Drug Delivery, Taylor & Francis, 2015, 12 (8), pp.1209-1223. 〈10.1517/17425247.2015.1028916〉. 〈hal-01280370〉
    • David Attivi, Stéphane Gibaud. Continuous infusion of piperacillin/tazobactam in patients with severe infections: A possible pharmacokinetic optimisation?. Annales Pharmaceutiques Françaises, Elsevier Masson, 2014, 72 (3), pp.146-151. 〈10.1016/j.pharma.2013.12.006〉. 〈hal-01291788〉
    • David Attivi, Gaétan Kosmalski, Claire Zeghmouli, Stéphane Gibaud. Effect of intravenous hydration in patients receiving bisphosphonate therapy. International Journal of Clinical Pharmacy, 2014, 36 (6), pp.1277-1281. 〈http://link.springer.com〉. 〈10.1007/s11096-014-9994-x〉. 〈hal-01169102〉
    • R. Alfonsi, D. Attivi, A. Astier, Marie Socha, S. Morice, et al.. Characterization of mitotane (o,p′-DDD) – cyclodextrin inclusion complexes: Phase-solubility method and NMR. Annales Pharmaceutiques Françaises, Elsevier Masson, 2013, 71 (3), pp.186-92. 〈10.1016/j.pharma.2013.02.001〉. 〈hal-01290439〉
    • Selma Becherirat, Marie-Claire Lanhers, Marie Socha, Mehdi Yemloul, Alain Astier, et al.. The antitumor effects of an arsthinol–cyclodextrin complex in a heterotopic mouse model of glioma. European Journal of Pharmaceutics and Biopharmaceutics, Elsevier, 2013, 83 (3 Pt A), pp.560-568. 〈http://www.sciencedirect.com/science/article/pii/S0939641113002403〉. 〈10.1016/j.ejpb.2013.06.021〉. 〈hal-01169157〉
    • Stéphane Gibaud, David Attivi. Microemulsions for oral administration and their therapeutic applications.. Expert Opinion on Drug Delivery, Taylor & Francis, 2012, 9 (8), epub ahead of print. 〈http://informahealthcare.com/doi/abs/10.1517/17425247.2012.694865〉. 〈10.1517/17425247.2012.694865〉. 〈hal-00706176〉
    • Jean Rodgers, Amy Jones, Stéphane Gibaud, Barbara Bradley, Christopher Mccabe, et al.. Melarsoprol Cyclodextrin Inclusion Complexes as Promising Oral Candidates for the Treatment of Human African Trypanosomiasis. PLoS Neglected Tropical Diseases, Public Library of Science, 2011, 5 (9), pp.e1308. 〈10.1371/journal.pntd.0001308〉. 〈hal-00689712〉
    • David Attivi, Imane Ajana, Alain Astier, Béatrice Demoré, Stéphane Gibaud. Development of microemulsion of mitotane for improvement of oral bioavailability.. Drug Development and Industrial Pharmacy, Taylor & Francis, 2010, 36 (4), pp.421-7. 〈10.3109/03639040903225083〉. 〈hal-00689714〉
    • Stéphane Gibaud, Gérard Jaouen. Arsenic-Based Drugs: From Fowler’s Solution to Modern Anticancer Chemotherapy. Topics in Organometallic Chemistry, Springer Verlag, 2010, 32, pp.1-20. 〈10.1007/978-3-642-13185-1〉. 〈hal-01395677〉
    • Imane Ajana, Alain Astier, Stéphane Gibaud. Speciation of arsenic in urine following intravenous administration of arsthinol in mice.. European journal of drug metabolism and pharmacokinetics, 2010, 35 (1-2), pp.59-65. 〈hal-00689713〉
    • Imane Ajana, Alain Astier, Stéphane Gibaud. Arsthinol nanosuspensions: pharmacokinetics and antileukemic activity on NB4 promyelocytic leukemia cells. J Pharm Pharmacol, 2009, 61 (10), pp.1295-301. 〈10.1211/jpp/61.10.0004〉. 〈hal-00689719〉
    • Siham Ben Zirar, Alain Astier, Marc Muchow, Stéphane Gibaud. Comparison of nanosuspensions and hydroxypropyl-beta-cyclodextrin complex of melarsoprol: pharmacokinetics and tissue distribution in mice.. European Journal of Pharmaceutics and Biopharmaceutics, Elsevier, 2008, 70 (2), pp.649-56. 〈10.1016/j.ejpb.2008.05.012〉. 〈hal-00399636〉
    • Siham Ben Zirar, Stéphane Gibaud, Camut Alexandra, Alain Astier. Pharmacokinetics and tissue distribution of the antileukaemic organoarsenicals arsthinol and melarsoprol in mice. Journal of Organometallic Chemistry, Elsevier, 2007, 692 (6), pp.1348-1352. 〈10.1016/j.jorganchem.2006.10.034〉. 〈hal-01395675〉
    • Stéphane Gibaud, A. Astier. [Organoarsenicals derived from 2-phenyl-[1,3,2]dithiarsolan-4-yl)-methanol (AsIII) with antileukaemic properties: from trypanosomicides to anticancer drugs]. Annales Pharmaceutiques Françaises, Elsevier Masson, 2007, 65 (3), pp.162-8. 〈hal-00399635〉
    • Stéphane Gibaud, Raphaël Alfonsi, Pierre Mutzenhardt, Isabelle Fries, Alain Astier. (2-Phenyl-[1,3,2]dithiarsolan-4-yl)-methanol derivatives show in vitro antileukemic activity. Journal of Organometallic Chemistry, Elsevier, 2006, 691, pp.1081-1084. 〈10.1016/j.jorganchem.2005.11.007〉. 〈hal-00125073〉
    • H. Brun, M. Paul, N. Razzouq, M. Binhas, Stéphane Gibaud, et al.. Cyclodextrin inclusion complexes of the central analgesic drug nefopam.. Drug Development and Industrial Pharmacy, Taylor & Francis, 2006, 32 (10), pp.1123-34. 〈10.1080/03639040600920663〉. 〈hal-00399631〉
    • Stéphane Gibaud, Siham Ben Zirar, Pierre Mutzenhardt, Isabelle Fries, Alain Astier. Melarsoprol-cyclodextrins inclusion complexes.. International Journal of Pharmaceutics, Elsevier, 2005, 306 (1-2), pp.107-21. 〈10.1016/j.ijpharm.2005.09.003〉. 〈hal-00399630〉
    • Stéphane Gibaud, Najim Jabir Al Awwadi, Camille Ducki, Alain Astier. Poly(epsilon-caprolactone) and Eudragit microparticles containing fludrocortisone acetate.. International Journal of Pharmaceutics, Elsevier, 2004, 269 (2), pp.491-508. 〈hal-00399629〉
    • Stéphane Gibaud, Adela Gaia, Alain Astier. Slow-release melarsoprol microparticles.. International Journal of Pharmaceutics, Elsevier, 2002, 243 (1-2), pp.161-6. 〈hal-00399626〉
    • Stéphane Gibaud, Aurélie Bonneville, Alain Astier. Preparation of 3,4-diaminopyridine microparticles by solvent-evaporation methods.. International Journal of Pharmaceutics, Elsevier, 2002, 242 (1-2), pp.197-201. 〈hal-00399627〉
    • S. Gibaud, C. Weingarten, J. P. Andreux, P. Couvreur. [Targeting bone marrow with the help of polyalkylcyanoacrylate nanoparticles]. Annales Pharmaceutiques Françaises, Elsevier Masson, 1999, 57 (4), pp.324-31. 〈hal-00399628〉
    • Marie-Estelle Page-Clisson, Stéphane Gibaud, Huguette Pinto-Alphandary, Colette Weingarten, Patrick Couvreur. Polyisobutylcyanoacrylate nanoparticles as drug carriers: influence of sulfur dioxide on the physico-chemical characteristics of ciprofloxacin- and doxorubicin-loaded nanoparticles. International Journal of Pharmaceutics, Elsevier, 1998, 166, pp.117 - 120. 〈10.1016/S0378-5173(98)00028-3〉. 〈hal-01383588〉
    • S. Gibaud, C. Rousseau, C. Weingarten, R. Favier, L. Douay, et al.. Polyalkylcyanoacrylate nanoparticles as carriers for granulocyte-colony stimulating factor (G-CSF).. Journal of Controlled Release, Elsevier, 1998, 52 (1-2), pp.131-9. 〈hal-00399625〉
    • M. Demoy, Stéphane Gibaud, J. P. Andreux, C. Weingarten, B. Gouritin, et al.. Splenic trapping of nanoparticles: complementary approaches for in situ studies.. Pharmaceutical Research, American Association of Pharmaceutical Scientists, 1997, 14 (4), pp.463-8. 〈hal-00689718〉
    • S. Gibaud, M. Demoy, J. P. Andreux, C. Weingarten, B. Gouritin, et al.. Cells involved in the capture of nanoparticles in hematopoietic organs.. Journal of Pharmaceutical Sciences, Wiley, 1996, 85 (9), pp.944-50. 〈10.1021/js960032d〉. 〈hal-00399624〉
    • Stéphane Gibaud, Andreux Jean-Paul, Colette Weingarten, Michèle Renard, Patrick Couvreur. Increased bone marrow toxicity of doxorubicin bound to nanoparticles. European Journal of Cancer, Elsevier, 1994, 30A (6), pp.820-826. 〈http://www.sciencedirect.com/science/article/pii/0959804994902992〉. 〈10.1016/0959-8049(94)90299-2〉. 〈hal-01383605〉
    • S. Gibaud, J. P. Andreux, C. Weingarten, Maurice Renard, P. Couvreur. Increased bone marrow toxicity of doxorubicin bound to nanoparticles.. European Journal of Cancer, Elsevier, 1994, 30A (6), pp.820-6. 〈hal-00399622〉
    • F Decool, V Goury, A Tibi, S Gibaud, F Vincent, et al.. Detection of bacterial adenosine triphosphate through bioluminescence, applied to a rapid sterility test of injectable preparations. Analytica Chimica Acta, Elsevier Masson, 1991, 255, pp.423 - 425. 〈10.1016/0003-2670(91)80078-8〉. 〈hal-01383025〉

    Communication dans un congrès1 document

    • C. Lapointe, J.P. Grandhaye, S. Gibaud. Contribution de la démarche d'auto-évaluation à l'autonomisation des professionnels : application à une Unité Centralisée pour la préparation des Cytotoxiques du réseau Oncolor. 3ème conférence francophone en gestion et ingénierie des systèmes hospitaliers (GISEH), Sep 2006, LUXEMBOURG, Luxembourg. 2006. 〈hal-00167643〉